Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Their research and development focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology and applying their capabilities in human genetics, advanced technologies, vaccines and medicines development.

About the Oxford-GSK Alliance

GSK and the University of Oxford work collaboratively on research projects in functional genomics, digital biomarkers, neurodegeneration, immunology, and pain.  These projects aim to transform the understanding of how genetics influence disease and enable the identification of novel and high-quality validated targets and derive novel digital biomarkers to develop clinically meaningful outcome measures.

Building on this strong relationship, the multi-disciplinary Oxford-GSK Institute of Molecular and Computational Medicine (IMCM) was launched in 2022, pioneering a new model of academic-industry collaboration. Initially focussing on neurodegenerative diseases, the aim of the Institute is to improve tools in, and knowledge from, genetics, genomics, molecular and single cell biology, spatial imaging, machine learning and novel methods of data handling to study the pattern of diseases in new ways.

GSK logo. White on orange